http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
-
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
-
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
Korro to Present at the TD Cowen 46th Annual Health Care Conference
-
Korro to Host Virtual Analyst Day on January 27, 2026
-
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Korro Bio reports mixed results from KRRO-110 trial, cuts workforce by third
-
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
-
Korro to Participate in Upcoming Investor and Scientific Conferences
-
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
Korro Bio receives European orphan drug designation for KRRO-110
-
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
-
Korro to Participate in Upcoming Investor Conferences
-
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
-
Korro Bio (KRRO) Appoints Loïc Vincent as Chief Scientific Officer
-
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
-
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
-
Korro Bio (KRRO): KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
-
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

